Biotech


  • Bristol Myers sign
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s

    The Alzheimer’s space is booming, from a new use for a schizophrenia drug to discovered pathways linked to the disease — but there’s been stumbles too.

    By Oct. 11, 2024
  • Microscope blood slide
    Image attribution tooltip
    Motortion via Getty Images
    Image attribution tooltip

    Regeneron takes the long-haul approach to oncology, stumbles and all

    Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.

    By Oct. 10, 2024
  • cancer healthcare Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Oncology

    As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

    By PharmaVoice staff
  • Futuristic medicine research gene therapy health analysis vector illustration.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As AI transforms drug development, biotechs might not need as much Big Pharma support

    Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.

    By Oct. 9, 2024
  • Boxes bearing the brand name Wegovy are arranged on a table.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds

    Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.

    By Kelly Bilodeau • Oct. 7, 2024
  • brain scan hand
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?

    Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.

    By Oct. 4, 2024
  • FluMist
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip

    Flu vaccination rates are falling despite record child deaths. Can innovation save the day?

    As respiratory disease season approaches, experts are concerned about vaccination rates — but the industry is churning out new solutions to help.

    By Oct. 3, 2024
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Honglouwawa via Getty Images
    Image attribution tooltip

    Kailera Therapeutics emerges from stealth with $400M for obesity drugs

    The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.”

    By Gwendolyn Wu • Oct. 2, 2024
  • business executives mingling in a conference building
    Image attribution tooltip
    hxdbzxy via Getty Images
    Image attribution tooltip

    Top pharma and biotech conferences 2025

    Mark your calendars for the most important industry conferences in 2025.

    By Oct. 1, 2024
  • Joe Panetta
    Image attribution tooltip
    Permission granted by Biocom
    Image attribution tooltip
    Q&A

    California is a life sciences leader. Joe Panetta has been one of its most vocal advocates.

    The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.

    By Alexandra Pecci • Oct. 1, 2024
  • lab cell hands
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?

    The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.

    By Kelly Bilodeau • Sept. 30, 2024
  • studying brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades

    The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.

    By Kelly Bilodeau • Sept. 26, 2024
  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Image attribution tooltip
    Q&A

    Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters

    Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.

    By Sept. 26, 2024
  • A photo of Bluebird bio signage in a corporate lobby
    Image attribution tooltip
    Permission granted by Bluebird bio
    Image attribution tooltip

    Bluebird to lay off another 25% of workforce in latest restructuring

    The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.

    By Delilah Alvarado • Sept. 25, 2024
  • eye dna helix
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Fresh data intensifies race for a major gene therapy target

    4D Molecular Therapeutics reported positive interim analysis in the high-potential wet AMD indication last week.

    By Sept. 25, 2024
  • Alicia Zhou, CEO, Cancer Research Institute
    Image attribution tooltip
    Permission granted by CRI
    Image attribution tooltip
    Q&A // First 90 Days

    Want better cancer treatments? Make biopharma more like Silicon Valley

    Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.

    By Sept. 24, 2024
  • Federal Reserve chairman Jerome Powell speaks at a news conference on Sept. 18, 2024.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    What the Fed’s rate cut means for biotech

    Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

    By Ben Fidler • Sept. 20, 2024
  • Meg Alexander headshot
    Image attribution tooltip
    Permission granted by Ovid Therapeutics
    Image attribution tooltip

    After epilepsy setback, Ovid charges confidently ahead in CNS

    A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.

    By Sept. 20, 2024
  • FDA headquarters with sign in foreground
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Getting IND ready — how companies can avoid common traps

    Overpromising, overcommitting and neglecting CMC are a few of the pitfalls that cause sponsors to stumble when submitting a new drug application.

    By Alexandra Pecci • Sept. 18, 2024
  • brain scan
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The hunt for game-changers against the deadliest form of brain cancer

    Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.

    By Kelly Bilodeau • Sept. 16, 2024
  • Capitol Hill lit up at night
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Biopharma prepares to pivot from China as Biosecure Act advances

    After the House of Representatives passed the Biosecure Act last week, U.S. biotechs could be  forced to cut ties with five Chinese contract partners.

    By Sept. 16, 2024
  • Biotech investment
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Who’s winning in biotech’s tight market?

    Three of the largest fundraising rounds in 2024 show where investors are willing to place their bets in biotech.

    By Sept. 13, 2024
  • Pharmaceutical cartons with the logo for Bristol Myers Squibb's Opdivo rest on a refrigerator shelf.
    Image attribution tooltip

    George Frey/Reuters

    Image attribution tooltip
    Deep Dive

    A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

    Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

    By Jonathan Gardner • Sept. 10, 2024
  • Drug money
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    A new way of determining a drug’s value — with health equity in mind

    Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health. 

    By Sept. 10, 2024
  • A flag flies above the headquarters campus of Eli Lilly
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies

    The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.

    By Sept. 9, 2024
  • Brain disorder
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Huntington’s disease R&D is regaining ground after several disappointments

    Setbacks haven’t stopped advances by biotechs and pharmas working on new drugs for the inherited brain disorder.

    By Kelly Bilodeau • Sept. 9, 2024